| Literature DB >> 34343695 |
Kathryn Peterson1, Ekaterina Safroneeva2, Alain Schoepfer3.
Abstract
Besides eosinophilic esophagitis, other eosinophilic gastrointestinal diseases (EGIDs), such as eosinophilic gastritis, eosinophilic gastroenteritis, and eosinophilic colitis, are increasingly diagnosed over the last decade. Whereas diagnosis and therapy of eosinophilic esophagitis have been standardized, the diagnosis and therapy of other EGIDs are areas of active research. Motivated by the increasing prevalence of these conditions, concerted efforts of different stakeholders have led to the evaluation of targeted biologic therapies for EGID management over the last couple of years, and several promising molecules are currently in the pipeline. This review article provides an overview of targeted biologic therapies for use in EGIDs.Entities:
Year: 2021 PMID: 34343695 DOI: 10.1016/j.jaip.2021.07.031
Source DB: PubMed Journal: J Allergy Clin Immunol Pract